The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
 
Hyunseok Kang
Honoraria - Axis Medical Education; Cancer Expert Now
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Coherus Biosciences; Exelixis; GlaxoSmithKline; MitoImmune; PIN therapeutics; Prelude Therapeutics; Tempus
Research Funding - Ayala Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst); NeoImmuneTech (Inst); PDS Biotechnology (Inst); Prelude Therapeutics (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Bhumsuk Keam
Honoraria - Lilly; Merck; Yuhan
Consulting or Advisory Role - CBS Bioscience; Handok; ImmuneOncia; NeoImmuneTech; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Daniel W. Bowles
Consulting or Advisory Role - Blueprint Medicines; Exelixis
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Regeneron; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); TopAlliance BioSciences Inc (Inst)
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Endocrine Society; Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Ayala Pharmaceuticals; Cellestia Biotech; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks; Neogene Therapeutics; TC Corp
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; eisai; Exelixis; Loxo; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Tak Yun
No Relationships to Disclose
 
Seong Jang
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Xianzhang Meng
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Elevar Therapeutics
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi; SIRPant Immunotherapeutics
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP